Analysis of influential factors for the failure of tigecycline in the treatment of multidrug-resistant Acinetobacter baumannii pneumonia
- VernacularTitle:替加环素治疗多重耐药鲍曼不动杆菌肺炎失败的影响因素分析
- Author:
Guoxian SUN
1
;
Yuan XU
1
;
Weili LIU
2
;
Hongling HOU
3
;
Wenxing YIN
1
Author Information
1. Dept. of Clinical Pharmacy，the Affiliated Hospital of Yangzhou University，Jiangsu Yangzhou 225001，China
2. Dept. of Critical Care Unit，the Affiliated Hospital of Yangzhou University，Jiangsu Yangzhou 225001，China
3. Dept. of Neurology，the Affiliated Hospital of Yangzhou University，Jiangsu Yangzhou 225001，China
- Publication Type:Journal Article
- Keywords:
tigecycline;
multidrug-resistant Acinetobacter baumannii;
pneumonia;
treatment failure;
influential factor
- From:
China Pharmacy
2022;33(22):2775-2778
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE To explore the factors influencing the failure of tigecycline in the treatment of multidrug-resistant Acinetobacter baumannii （MDRAb） pneumonia， and to provide a basis for the rational use of tigecycline. METHODS The information of patients with MDRAb pneumonia who were treated with tigecycline in the ICU of our hospital during Aug. 2020-Jun. 2022 were collected retrospectively. The patients were divided into treatment failure group and treatment success group according to the curative effect. The basic information， acute physiology and chronic health evaluation Ⅱ （APACHE-Ⅱ） score， laboratory indicators， and medication-related information were recorded and compared between 2 groups. Logistic regression analysis was conducted for analyzing the influential factors inducing the failure of tigecycline in the treatment of MDRAb pneumonia. RESULTS A total of 102 cases of MDRAb pneumonia received tigecycline therapy， with 71 in the treatment success group and 31 in the treatment failure group. Compared with the treatment success group， the patients in the treatment failure group had higher APACHE Ⅱ score （P＜0.05）， and more cases with abnormal coagulation function and comorbidities ≥2 types （P＜0.05）. After the treatment of tigecycline， procalcitonin level of the treatment failure group was significantly higher than that of the treatment success group （P＜0.05）. Logistic regression analysis showed that the independent risk factors for the failure of tigecycline in the treatment of MDRAb pneumonia included abnormal coagulation function and APACHE-Ⅱ score ≥20 （P＜0.05）； doubling the first dose was a protective factor （P＜0.05）. CONCLUSIONS In patients with MDRAb pneumonia with APACHE-Ⅱ score ≥20 and abnormal coagulation function， tigecycline therapy is more likely to fail； doubling the first dose of tigecycline has better efficacy in the treatment of MDRAb pneumonia.
